Melphalan flufenamide

DB16627ApprovedWithdrawnSmall moleculeAlkylating Drugs

Melphalan flufenamide is a melphalan prodrug used to treat relapsed or refractory multiple myeloma. Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases.

Chemical structure of Melphalan flufenamide
Mechanism
Curator reviewed · 14 references
Primary indication
Melphalan flufenamide is indicated in combination with dexamethasone to treat adults with relapsed or refractory multiple myeloma who have received ≥4 therapies and are refractory to at least one proteasome inhibitor, immunomodulatory agent, and anti-CD38...Curator reviewed · 1 structured indication
Formula / weight
C24H30Cl2FN3O3 · 498.42 g/mol (avg)
First approval
United States, 2021 · European Union, 2022
Also known as
Melflufen · MFF
Code names
J-1 · Prodrug J-1 · WHO 9493
Brand names
  • Pepaxti

Resolves to

Structure
InChIKeyYQZNKYXGZSVEHI-VXKWHMMOSA-NSMILESCCOC(=O)[C@H](CC1=CC=C(F)C=C1)NC(=O)[C@@H](N)CC1=CC=C(C=C1)N(CCCl)CCCl

What you can answer from here — as of July 17, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
10Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
3Marketed productsAcross 3 countries and 2 labellers
Sign in
1ATC codeIncluding every combination product, plus 15 drug categories
Sign in
16+ReferencesStructured and connected to the statements they support
Sign in

Which other approved drugs treat the same conditions as Melphalan flufenamide, and which companies have late-stage candidates in those indications?

Create a free account or log in to explore the full data card.

Create Account